Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

ArriVent BioPharma (AVBP) Shares Issued (2023 - 2026)

ArriVent BioPharma has reported Shares Issued over the past 4 years, most recently at $54.7 million for Q1 2026.

  • Quarterly results put Shares Issued at $54.7 million for Q1 2026, up 739.84% from a year ago — trailing twelve months through Mar 2026 was $48.7 million (down 74.69% YoY), and the annual figure for FY2025 was $502000.0, down 99.73%.
  • Shares Issued reached $54.7 million in Q1 2026 per AVBP's latest filing, up from $84000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $185.9 million in Q3 2024 and bottomed at -$6.1 million in Q2 2025.
  • Median Shares Issued over the past 4 years was $46500.0 (2024), compared with a mean of $20.1 million.
  • Peak annual rise in Shares Issued hit 651500.0% in 2025, while the deepest fall reached 14070.45% in 2025.
  • Over 4 years, Shares Issued stood at $285000.0 in 2023, then soared by 65129.82% to $185.9 million in 2024, then crashed by 99.95% to $84000.0 in 2025, then soared by 65047.62% to $54.7 million in 2026.
  • Business Quant data shows Shares Issued for AVBP at $54.7 million in Q1 2026, $84000.0 in Q4 2025, and $49000.0 in Q3 2025.